Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Starting soon · Phase 3

Conditions studied: Pulmonary Fibrosis

In brief

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Key facts

Study ID

NCT07441408

Run by

Bristol-Myers Squibb

People needed

2277

Starts

2026-12-16

Expected to finish

2030-03-30

Last updated by the study team

2026-07-28

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have completed participation in either IM027068 or IM0271015 (defined as receiving study intervention (IMP) until completion of EOT visit).

You may not qualify if…

• Clinically significant AE that resulted in discontinuation or interruption of IMP (Investigational Medicinal Product) in IM027068 or IM0271015 without reinitiation of IMP.
• Exhibit symptoms of heart failure at rest.
• History of lung reduction surgery or lung transplant. Note: Being on the transplantation list is allowed.
• Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single drug therapy that now requires multi-drug therapy.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Local Institution - 0111 — Ocala, Florida, United States
• Local Institution - 0119 — Philadelphia, Pennsylvania, United States
• Local Institution - 0013 — Florida, Vicente López, Buenos Aires, Argentina
• Local Institution - 0014 — Mar del Plata, Buenos Aires, Argentina
• Local Institution - 0007 — Quilmes, Buenos Aires, Argentina
• Local Institution - 0009 — San Juan Bautista, Buenos Aires, Argentina
• Local Institution - 0003 — Mar del Plata, B, Argentina
• Local Institution - 0001 — Córdoba, Córdoba Province, Argentina
• Local Institution - 0005 — CABA, Distrito Federal, Argentina
• Local Institution - 0002 — Godoy Cruz, Mendoza Province, Argentina
• Local Institution - 0011 — Mendoza, M, Argentina
• Local Institution - 0015 — Rosario, S, Argentina
• Local Institution - 0012 — San Miguel de Tucumán, Tucumán Province, Argentina
• Local Institution - 0010 — Buenos Aires, Argentina
• Local Institution - 0004 — Buenos Aires, Argentina
• Local Institution - 0016 — CABA, Argentina
• Local Institution - 0006 — Mendoza, Argentina
• Local Institution - 0008 — Santa Fe, Argentina
• Local Institution - 0287 — Camperdown, New South Wales, Australia
• Local Institution - 0290 — Chermside, Queensland, Australia
• Local Institution - 0291 — Greenslopes, Queensland, Australia
• Local Institution - 0293 — South Brisbane, Queensland, Australia
• Local Institution - 0289 — Adelaide, South Australia, Australia
• Local Institution - 0288 — Frankston, Victoria, Australia
• Local Institution - 0113 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.